Impact of antihypertensive therapy on cardiohemodynamic, metabolic parameters, level of apelin-12 and obestatin in patients with hypertension and diabetes mellitus type 2

Authors

  • Tabachenko E. S. Kharkiv National Medical University, Kharkov, Ukraine
  • Kravchun P. G. Kharkiv National Medical University, Kharkov, Ukraine
  • Ryndina N. G. Kharkiv National Medical University, Kharkov, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2017.1.03

Keywords:

arterial hypertension, diabetes mellitus type 2, apelin-12, obestatin, azilsartan medoxomil

Abstract

he study examined 67 patients with arterial hypertension with concomitant diabetes mellitus type 2 (mean age 60.03 ± 1.17). Aim was to evaluate the changes of structural and functional parameters of the myocardium, metabolic parameters, apelin-12 and obestatin on background antihypertensive therapy in patients with arterial hypertension and diabetes mellitus type 2. Combination of azilsartan medoxomil, metformin and rosuvastatin found more pronounced therapeutic effect on blood pressure normalizing both due to the systolic and diastolic, regardless of time of day, and also with decreasing the degree of myocardial remodeling by reducing left ventricular hypertrophy and the reduction of the left ventricular cavity in comparison with quinapril in combination with metformin and rosuvastatin in patients with arterial hypertension and diabetes mellitus type 2.

References

Kovalenko VM, Lutaj MI. Sercevo-sudynni zahvorjuvannja: rekomendacii’ z diagnostyky, profilaktyky ta likuvannja, Kyi’v, 2011: 408 p.

Djedova VO, Bojev SS, Docenko MJa, Shehunova IO. Arterial’naja Gipertenzija 2015; 1:45-49.

Syrenko JuN. Zdorovja Ukrai’ny 2015; 5:27.

Rekomendacii’ z dyferencijnoi’ diagnostyky arterial’nyh gipertenzij, Kyi’v, 2014.

Jermak OS, Kravchun PG, Ryndina NG, et al. Bukovyn Med Visn 2015; 1(73);65-68.

Turnbull F. Lancet 2003; 362:1527-1535. https://doi.org/10.1016/S0140-67360314739-3

Mancia G, Fagard R, Narkiewicz K, et al. Europ Heart J 2013; 34:2159-2219. https://doi.org/10.1093/eurheartj/eht308.P2159

Ruddy MC, Kostis JB, Oparil S, Weber MA. Hypertension 2000; 15:621-637.

Dahlof B, Devereux RB, Kjeldsen SE, et al. Lancet 2002; 359:995-1003. https://doi.org/10.1016/S0140-67360416456-8

Weber MA, Julius S, Kjeldsen SE, et al. Lancet 2004; 363:2049-2051.

Cohn JN, Tognoni G. N Engl J Med 2001; 345:1667-1675.

Brenner BM, Cooper ME, De Zeeuw D, et al. Engl J Med 2001; 345:861-869.

Lewis EJ, Hunsicker LG, Clarke WR, et al. N Engl J Med 2001: 345:851-860. https://doi.org/10.1056/NEJMoa011303

Klingbeil AU, Schneider M, Martus P, et al. Am J Med 2003; 115:41-46. https://doi.org/10.1016/S0002-93430300158-X

Elliott WJ,. Meyer PM. Lancet 2007; 369:201-207. https://doi.org/10.1016/S0140-67360760108-1

McMurray JJ, Holman RR, Haffner SM, et al. N Engl J Med 2010; 362:1477-1490. https://doi.org/10.1056/NEJMcp0909392

Yusuf S, Teo KK, Pogue J, et al. N Engl J Med 2008; 358:1547-1569. https://doi.org/10.1056/NEJMoa0801317

Downloads

Published

2017-02-20

How to Cite

Tabachenko, E. S., Kravchun, P. G., & Ryndina, N. G. (2017). Impact of antihypertensive therapy on cardiohemodynamic, metabolic parameters, level of apelin-12 and obestatin in patients with hypertension and diabetes mellitus type 2 . Problems of Endocrine Pathology, 59(1), 25-32. https://doi.org/10.21856/j-PEP.2017.1.03

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 > >>